Pfizer Inc. 's (NYSE: PFE ) stock price continued stagnating over the last three months, which reinforces my cautious stance I discussed in November . Despite being one of a few companies that helped to save theComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analysis of public companies paid off and now I feel very confident i ...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.Which of these two high-yield dividend payers is best for your portfolio? Let's weigh their strong points against some of the challenges they face, to see which stock is a better buy now.The case for MerckShares of Merck have fallen ...

The past three years have been difficult for Pfizer (PFE -0.35%). The pharmaceutical giant's financial results worsened substantially as its coronavirus-related tailwind came to a screeching halt. Investors responded by sending the stock down significantly. Pfizer has lost about 50% of its market value in the past three years. If the stock can bounce back and deliver excellent returns over the long run, initiating a position today might be a great idea. Are there good reasons to think Pfizer has what it tak ...

CHINA - 2024/09/21: In this photo illustration, a Pfizer logo is displayed on the screen of a ... [+] smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesPfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per share, compared to the consensus estimates of $17.4 billion and $0.46, respectiv ...

Pfizer (PFE) reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar. Revenues came in at $17.76 billion, up 22% from the year-ago quarter on a reported basis. Revenues reflected an operational increase of 21% and a positive currency impact of 1%. Total revenues also beat the Zacks C ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Pfizer (PFE) reported $17.76 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 24.7%. EPS of $0.63 for the same period compares to $0.10 a year ago.The reported revenue represents a surprise of +1.52% over the Zacks Consensus Estimate of $17.5 billion. With the consensus EPS estimate being $0.48, the EPS surprise was +31.25%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine th ...

Pfizer (PFE) announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its oncology drug, Braftovi (encorafenib), for treating patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation. Braftovi is an oral small-molecule kinase inhibitor that targets BRAF V600E.The phase III BREAKWATER study is evaluating the candidate's safety and efficacy in combination with Eli Lilly’s (LLY) Erbitux (cetuximab) and chemotherapy (mFOLFOX6) in mCR ...

Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.Pharmaceuticals giant Pfizer (PFE 0.25%) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. The company reported an adjusted earnings per share of $0.63, significantly above the analyst consensus of $0.47, while generating revenue of $17.76 billion, surpassing expectations of $17.35 billion. Despite a significant year-over-year decl ...

Pfizer (PFE) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 31.25%. A quarter ago, it was expected that this drugmaker would post earnings of $0.64 per share when it actually produced earnings of $1.06, delivering a surprise of 65.63%.Over the last four quarters, the company has surp ...